You're browsing HLTH 2018's website. Visit to explore this year's edition!

Main caricature of Jessica Grossman, MD, who is speaking at HLTH and is CEO at Medicines360 Overlay caricature of Jessica Grossman, MD, who is speaking at HLTH and is CEO at Medicines360

Jessica Grossman, MD



Jessica Grossman, MD is the CEO of Medicines360, a non-profit, mission-driven women’s health pharmaceutical company. She has been a board member of Medicines360 since 2011. Dr. Grossman is a seasoned industry executive with a proven track record leading successful women’s health companies. As a medical technology executive, she brings a wealth of experience in product development and commercialization and the ability to accelerate profitable business models. Prior to joining Medicines360, Dr. Grossman served as president and Founding CEO of Sense4Baby, Inc., where she closed a $4-million series A investment and within 18 months of joining the organization led the company to a successful acquisition following FDA clearance, CE mark, and early commercialization. Dr. Grossman was also Founder and President of Gynesonics, an early stage medical device company focused on minimally invasive solutions for women’s health, where she raised over $22 million in venture capital financing. Under her leadership, the team invented and developed the first intrauterine ultrasound guided radiofrequency ablation device for fibroid tumors.

She has also been a Medical Director at Ethicon Endo-Surgery, part of the Johnson and Johnson family of companies. Dr. Grossman holds numerous patents and has published several peer reviewed articles. She has performed research at the Beth Israel Deaconess Medical Center, one of the teaching hospitals of Harvard Medical School. Dr. Grossman qualified as an OB/GYN, earned her MD from Sidney Kimmel Medical College at Thomas Jefferson University and her undergraduate degree with honors from Brandeis University.

Medicines360 is a nonprofit pharmaceutical company working to expand access to contraceptives for women regardless of their socioeconomic status, insurance coverage, or geographic location. Royalties from sales of M360’s IUD at private clinics are used to offer the IUD at low cost to safety-net eligible for the 340B drug discount program.